A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Kuemmel S.Campone M.Loirat D.Lopez R.L.Thaddeus Beck J.de Laurentiis M.Im S.-A.Kim S.-B.Kwong A.Steger G.G.Adelantado E.Z.Duhoux F.P.Greil R.Kuter I.YEN-SHEN LUTibau A.?zg?ro?lu M.Scholz C.W.Singer C.F.Vega E.Wimberger P.Zamagni C.Couillebault X.-M.Fan L.Guerreiro N.Mataraza J.Sand-Dejmek J.Chan A.2022-09-022022-09-0220221078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123388323&doi=10.1158%2f1078-0432.CCR-20-3955&partnerID=40&md5=4bc8ffa602ef63c2fef595ffc098f8dchttps://scholars.lib.ntu.edu.tw/handle/123456789/617770[SDGs]SDG3A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancerjournal article10.1158/1078-0432.CCR-20-3955346157192-s2.0-85123388323